{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T04:28:21Z","timestamp":1725164901327},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Adv Therapy"],"published-print":{"date-parts":[[2012,8]]},"DOI":"10.1007\/s12325-012-0039-3","type":"journal-article","created":{"date-parts":[[2012,8,17]],"date-time":"2012-08-17T10:54:28Z","timestamp":1345200868000},"page":"691-697","source":"Crossref","is-referenced-by-count":19,"title":["Etanercept and Adalimumab Treatment Patterns in Psoriatic Arthritis Patients Enrolled in a Commercial Health Plan"],"prefix":"10.1007","volume":"29","author":[{"given":"Benjamin","family":"Chastek","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathleen M.","family":"Fox","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Crystal","family":"Watson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shravanthi R.","family":"Gandra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,8,16]]},"reference":[{"key":"39_CR1","doi-asserted-by":"crossref","unstructured":"Dhir V, Aggarwal A. Psoriatic arthritis: a critical review. Clin Rev Allergy Immunol. 2012. [Epub ahead of print].","DOI":"10.1007\/s12016-012-8302-6"},{"key":"39_CR2","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/1477-7525-7-25","volume":"7","author":"F. Salaffi","year":"2009","unstructured":"Salaffi F, Carotti M, Gasparini S, Intorcia M, Grassi W. The health-related quality of life in rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis: a comparison with a selected sample of healthy people. Health Qual Life Outcomes. 2009;7:25.","journal-title":"Health Qual Life Outcomes"},{"key":"39_CR3","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1136\/annrheumdis-2011-200387","volume":"71","author":"V. Strand","year":"2012","unstructured":"Strand V, Sharp V, Koenig AS, et al. Comparison of health-related quality of life in rheumatoid arthritis, psoriatic arthritis and psoriasis and effects of etanercept treatment. Ann Rheum Dis. 2012;71:1143\u20131150.","journal-title":"Ann Rheum Dis"},{"key":"39_CR4","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1093\/rheumatology\/ker216","volume":"51","author":"W. Tillett","year":"2012","unstructured":"Tillett W, de-Vries C and McHugh NJ. Work disability in psoriatic arthritis: a systematic review. Rheumatology (Oxford). 2012;51:275\u2013283.","journal-title":"Rheumatology (Oxford)"},{"key":"39_CR5","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1093\/rheumatology\/keq131","volume":"49","author":"S.M. Verstappen","year":"2010","unstructured":"Verstappen SM, Watson KD, Lunt M, McGrother K, Symmons DP, Hyrich KL. Working status in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford). 2010;49:1570\u20131577.","journal-title":"Rheumatology (Oxford)"},{"key":"39_CR6","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1093\/rheumatology\/keq182","volume":"49","author":"C.D. Poole","year":"2010","unstructured":"Poole CD, Lebmeier M, Ara R, Rafia R, Currie CJ. Estimation of health care costs as a function of disease severity in people with psoriatic arthritis in the UK. Rheumatology (Oxford). 2010;49:1949\u20131956.","journal-title":"Rheumatology (Oxford)"},{"key":"39_CR7","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.3899\/jrheum.090988","volume":"37","author":"T.Y. Zhu","year":"2010","unstructured":"Zhu TY, Tam LS, Leung YY, et al. Socioeconomic burden of psoriatic arthritis in Hong Kong: direct and indirect costs and the influence of disease pattern. J Rheumatol. 2010;37:1214\u20131220.","journal-title":"J Rheumatol"},{"key":"39_CR8","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1093\/rheumatology\/ken320","volume":"47","author":"I. Olivieri","year":"2008","unstructured":"Olivieri I, de Portu S, Salvarani C, et al. The psoriatic arthritis cost evaluation study: a cost-of-illness study on tumour necrosis factor inhibitors in psoriatic arthritis patients with inadequate response to conventional therapy. Rheumatology (Oxford). 2008;47:1664\u20131670.","journal-title":"Rheumatology (Oxford)"},{"key":"39_CR9","doi-asserted-by":"crossref","first-page":"27","DOI":"10.3899\/jrheum.091463","volume":"85","author":"E.C. Keystone","year":"2010","unstructured":"Keystone EC, Ware CF. Tumor necrosis factor and anti-tumor necrosis factor therapies. J Rheumatol Suppl. 2010;85:27\u201339.","journal-title":"J Rheumatol Suppl"},{"key":"39_CR10","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1002\/art.20335","volume":"50","author":"P.J. Mease","year":"2004","unstructured":"Mease PJ, Kivitz AJ, Burch FX, et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum. 2004;50:2264\u20132272.","journal-title":"Arthritis Rheum"},{"key":"39_CR11","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1002\/art.21306","volume":"52","author":"P.J. Mease","year":"2005","unstructured":"Mease PJ, Gladman DD, Ritchlin CT, et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2005;52:3279\u20133289.","journal-title":"Arthritis Rheum"},{"key":"39_CR12","unstructured":"Enbrel\u00ae (etanercept). Prescribing information, medication guide, and instructions for use. Available at: www.enbrel.com\/prescribinginformation.jspx . Accessed Jul 26 2012."},{"key":"39_CR13","unstructured":"Humira\u00ae (adalimumab). Full prescribing information. Available at: www.rxabbott.com\/pdf\/humira.pdf . Accessed Jul 26 2012."},{"key":"39_CR14","doi-asserted-by":"crossref","first-page":"R52","DOI":"10.1186\/ar2670","volume":"11","author":"A.A. Saad","year":"2009","unstructured":"Saad AA, Ashcroft DM, Watson KD, Hyrich KL, Noyce PR, Symmons DP. Persistence with antitumour necrosis factor therapies in patients with psoriatic arthritis: observational study from the British Society of Rheumatology Biologics Register. Arthritis Res Ther. 2009;11:R52.","journal-title":"Arthritis Res Ther"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.springerlink.com\/index\/pdf\/10.1007\/s12325-012-0039-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,20]],"date-time":"2017-06-20T22:58:02Z","timestamp":1497999482000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12325-012-0039-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8]]},"references-count":14,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2012,8]]}},"alternative-id":["39"],"URL":"https:\/\/doi.org\/10.1007\/s12325-012-0039-3","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,8]]}}}